EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches

Mingwei Wu, Yiyuan Chen, Gao Hua iD, Liu Chunhui

Immunity, Inflammation and Disease · 2023

DOI: 10.1002/iid3.1022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2023. Verfasst von Mingwei Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Qinzhou First People's Hospital, Qinzhou, China. Hauptthemen laut MEDLINE: Glioma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Low‐grade gliomas (LGGs) are currently considered a premalignant condition for high‐grade gliomas (HGGs) and are characterized by a relatively intact immune system. Immunotherapeutic modalities may offer a safe and effective treatment option for these patients. However , the CD2–CD58 axis, an important component of the immunological synapse, remains unknown in LGG.

Methods

RNA‐seq data from TCGA databases were analyzed. Immune cell infiltration was determined using a single‐sample gene set enrichment analysis (ssGSEA) based on integrated immune gene sets from published studies. Kaplan–Meier survival analysis, univariate and multivariate logistic analysis, and the ESTIMATE algorithm were employed to evaluate the impact of the CD2–CD58 axis on adult LGG patients.

Results

The expression of the CD2–CD58 axis was found to be elevated with increasing of WHO grade ( p < .05). Uni‐ and multi‐variable logistic analysis demonstrated that age, WHO grade, and CD58 levels were associated with poor prognosis in LGG patients with ( p < .01). MetaSape pathways analysis revealed the involvement of CD58 in regulating T cell activation, leukocyte‐mediated immunity, and the positive regulation of cell activation in WHO grade II and III. CD58 expression correlated with infiltrations of CD4+ lymphocytes, NK cells, and macrophages cells. The ESTIMATE algorithm indicated that patients with high CD58 expression had significantly higher immune scores compared with low CD58 expression in WHO grade II/III, but no statistical difference was observed in WHO grade IV ( p < .05). Furthermore, correlation analysis demonstrated the significant association between CD58 and CD274 ( r = 0.581, p < .001), HAVCR2 ( r = 0.58i7, p < .001), and LGALS9 ( r = 0.566, p < .001). Immunohistochemical staining further confirmed the relationship of CD58, HAVCR2, WHO grade, and prognosis in grade II and III patients.

Conclusion

Overall, our findings highlight the significant association between the CD2–CD58 axis and poor survival in LGG patients. High CD58 expression is implicated in T cell‐mediated immune responses as an immunosuppressive factor and affect inhibitory immune checkpoint genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaAdultHumansImmunity, CellularKaplan-Meier EstimateLymphocyte ActivationPrognosisCD2 AntigensCD58 Antigens

Stichwörter der Autor:innen

CD2CD58immune infiltrationinhibitory immune checkpointlow-grade gliomaprognosis

Substanzen

CD2 AntigensCD58 Antigens

Autor:innen und Institutionen

  • Qinzhou First People's Hospital, Qinzhou, China.
  • Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Gao Hua

Zitieren

APA

Wu, M., Chen, Y., Hua, G., & Chunhui, L. (2023). The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1022

Vancouver

Wu M, Chen Y, Hua G, Chunhui L. The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches. Immunity, Inflammation and Disease. 2023. doi:10.1002/iid3.1022

BibTeX
@article{Wu2023,
  author = {Wu, Mingwei and Chen, Yiyuan and Hua, Gao and Chunhui, Liu},
  title = {The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches},
  journal = {Immunity, Inflammation and Disease},
  year = {2023},
  doi = {10.1002/iid3.1022}
}
Kostenlos starten →